Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOL1 | O14791 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15103505 | 0.93 | APOL1 (0.33) | APOL1TDP1CA12CA1CA2 | |
| SCHEMBL4572780 | 0.86 | CA1 (0.39) | TDP1CA12CA1CA2CA9 | |
| SCHEMBL7766475 | 0.81 | TDP1 (0.31) | APOL1TDP1CA12CA1CA2 | |
| SCHEMBL193410 | 0.78 | CA12 (0.43) | CA12CA1CA2CA9 | |
| SCHEMBL21185836 | 0.78 | LMNA (0.39) | CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL6390746 | 0.76 | LMNA (0.38) | CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL26939020 | 0.76 | LMNA (0.38) | CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL12723119 | 0.74 | SSTR4 (0.41) | TDP1CA1CA2CHRNB2CHRNB4 | |
| SCHEMBL1553556 | 0.74 | POLB (0.43) | — | |
| SCHEMBL13163338 | 0.74 | SSTR4 (0.41) | TDP1CA1CA2CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7416721-B2 | Sunscreen compositions comprising insoluble organic UV-screening agents and hydroxyalkylurea compounds | L'OREAL (FR) | 2008-08-26 | — | — | US | claimed |
| EP-1535607-B1 | Increased moisturization efficacy using hydroxyalkylurea | AKZO NOBEL NV (NL) | 2013-07-17 | — | — | EP | disclosed |
| EP-1935878-B1 | Increased moisturization efficacy using hydroxyalkylurea | AKZO NOBEL NV (NL) | 2012-03-28 | — | — | EP | disclosed |
| US-7816310-B2 | Increased moisturization efficacy using hydroxyalkylurea and ammonium lactate | AKZO NOBEL N.V. (NL) | 2010-10-19 | — | — | US | disclosed |
| EP-1935878-A1 | Increased moisturization efficacy using hydroxyalkylurea | National Starch and Chemical Investment Holding Corporation (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1535607-A1 | Increased moisturization efficacy using hydroxyalkylurea | National Starch and Chemical Investment Holding Corporation (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113269-A1 | Increased moisturization efficacy using hydroxyalkylurea | NOURYON CHEMICALS INTERNATIONAL B.V. (NL) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113269-A1 | Increased moisturization efficacy using hydroxyalkylurea | CUTA, HRH2, XRCC6 | APOL1 2927/4885TDP1 1518/4885CA12 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.